Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates
Notably, the Mumbai-based nutrition startup TruNativ recently secured approximately $30 million (about Rs 283.5 crore) in its Series B funding round. Crucially, the global healthcare investment firm OrbiMed led this capital infusion. Consequently, this major investment highlights why preventive nutrition is now a critical clinical priority in India.
Historically, Indian consumers have remained severely underserved by typical dietary options. Specifically, many modern products promise health benefits but deliver unhealthy compromises, leading to widespread protein deficiencies. Furthermore, local populations face massive overexposure to refined sugars. Therefore, TruNativ developed clean-label products to address these daily clinical gaps in Indian households. Subsequently, OrbiMed senior executives Sunny Sharma and Sumona Chakraborty will join TruNativ’s board. As a result, the startup will combine strong corporate governance with a clear medical focus.
Indeed, the Mumbai-based company will utilize the newly raised capital to expand its nationwide distribution network. Specifically, this expansion will cover direct-to-consumer platforms, quick commerce, modern trade, and pharmacies. Additionally, TruNativ will deploy significant resources to scale its B2B2C ingredient business. Currently, this segment supplies science-backed nutrition solutions to several major consumer brands in India. Thus, doctors can expect a higher availability of healthier alternatives across various therapeutic categories. In addition, the brand plans to establish a new research and development center to drive medical food innovation.
Essentially, TruNativ operates across high-growth nutrition sectors including sugar substitutes, proteins, gut health, and beauty wellness. Since then, the company has focused on providing clean-label products. For instance, these products help patients manage diabetes risks and improve gastrointestinal function. Consequently, doctors can recommend these science-backed dietary choices to support ongoing therapeutic interventions. Ultimately, this significant capital injection will accelerate the accessibility of preventive healthcare options throughout India.
Q1: Who led the Series B funding round for TruNativ?
OrbiMed, a leading global healthcare investment firm, led the $30 million Series B funding round for TruNativ.
Q2: What are the main product categories offered by TruNativ?
TruNativ operates across key preventive nutrition areas, including sugar alternatives, protein supplements, gut health, and beauty wellness products.
Q3: How will TruNativ utilize the newly raised Series B funds?
The company will use the funds to expand its retail and pharmacy distribution network, grow its B2B2C ingredient division, and build a new R&D center.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
Mumbai-based startup TruNativ has raised $30 million in a Series B round led by OrbiMed. This investment highlights the growing importance of clean-label, nutrition-focused products to tackle India's widespread protein deficiency and sugar overexposure.
2 days back
A recent study by Corbett et al. highlights how elexacaftor/tezacaftor/ivacaftor (ETI) therapy for cystic fibrosis has led many patients to cease high-burden medications. This trend emphasizes the need to rationalize treatment regimens while maintaining patient safety.
Today
A study confirms that short-course preoperative endocrine therapy significantly reduces Ki67 levels in ER-positive breast cancer, with the MammaPrint assay acting as a key predictor of this functional response.
Today
Researchers from IIT Bombay, IISER Pune, and IISER Kolkata have discovered a novel peptide, KTDP, that blocks the motor protein kinesin-1 to lower blood lipids by 50%. Crucially, this mechanism does not cause fat buildup in the liver, offering a safer preclinical pathway for metabolic and cardiovascular therapy.
Today
Researchers have developed a facile method to prepare bone-targeting polypeptide nanoparticles using aza-Michael addition in aqueous environments. These biodegradable SCNPs offer adjustable size and stimuli-responsiveness, making them a promising platform for targeted orthopedic drug delivery.
Today
Researchers have developed a modular PEG-based scaffold that simplifies the creation of multi-agonist peptide therapeutics. Using GLP-1 and amylin agonists as a model, this platform enables rapid, modular assembly of potent multi-receptor drugs, offering a new route for treating obesity and metabolic diseases.
Today